LMAT earnings

BURLINGTON, Mass., April 14, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (NASDAQ:LMAT) announced today that it will release its first quarter 2026 financial results on Tuesday, May 5, 2026, after the market close. The company has scheduled a conference call for 5:00 PM EDT the same day to discuss the results, business highlights, and company outlook. Access to the live call is available by registering online here. All registrants will receive dial-in information and a PIN allowing them to access the live call. The audio webcast can also be accessed live or via replay at ir.lemaitre.com. About LeMaitre LeMaitre is a provider of devices, implants, and services for the treatment of pe

BURLINGTON, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (NASDAQ:LMAT), a provider of vascular devices, implants, and services, today reported Q4 2025 results, announced a quarterly dividend of $0.25/share (+25%), and provided guidance. Q4 2025: Sales $64.5mm, +16% (+15% organic) vs. Q4 2024Gross margin 71.7% (+240 bps)Op. income $18.8mm (+47%)Op. margin 29%Diluted EPS $0.68 (+39%)Cash up $16.1mm sequentially to $359.1mm Grafts (+27%), valvulotomes (+20%), and carotid shunts (+18%) drove Q4 sales growth. EMEA sales increased 29%, APAC 20%, and the Americas 10%. Gross margin of 71.7% (+240 bps) increased due to higher average selling prices and manufacturing efficien

BURLINGTON, Mass., Feb. 11, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (NASDAQ:LMAT) announced today that it will release its fourth quarter 2025 financial results on Wednesday, February 25, 2026, after the market close. The company has scheduled a conference call for 5:00 PM EST the same day to discuss the results, business highlights, and company outlook. Access to the live call is available by registering online here. All registrants will receive dial-in information and a PIN allowing them to access the live call. The audio webcast can also be accessed live or via replay at www.lemaitre.com/investor. About LeMaitre LeMaitre is a provider of devices, implants, and services for t

BURLINGTON, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (NASDAQ:LMAT), a provider of vascular devices, implants, and services, today reported Q3 2025 results, announced a quarterly dividend of $0.20/share, and provided guidance. Q3 2025 results include a non-recurring benefit from the Employee Retention Tax Credit. Non-GAAP adjusted figures exclude this benefit. A reconciliation of GAAP to non-GAAP results is included. Q3 2025: Sales $61.0mm, +11% (+12% organic)Gross margin 75.3% (+750 bps), adjusted 70.8% (+300 bps)Op. income $20.3mm (+54%), adjusted $16.9mm (+29%)Op. margin 33%, adjusted 28%Diluted EPS $0.75 (+54%), adjusted $0.62 (+27%)Cash up $23.6mm sequentiall

BURLINGTON, Mass., Oct. 09, 2025 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (NASDAQ:LMAT) announced today that it will release its third quarter 2025 financial results on Thursday, November 6, 2025, after the market close. The company has scheduled a conference call for 5:00 PM EST the same day to discuss the results, business highlights, and company outlook. Access to the live call is available by registering online here. All registrants will receive dial-in information and a PIN allowing them to access the live call. The audio webcast can also be accessed live or via replay at ir.lemaitre.com. About LeMaitre LeMaitre is a provider of devices, implants, and services for the treatment

BURLINGTON, Mass., Aug. 05, 2025 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (NASDAQ:LMAT), a provider of vascular devices, implants, and services, today reported Q2 2025 results, announced a quarterly dividend of $0.20/share, and provided guidance. Q2 2025: Sales $64.2mm, +15% (+15% organic)Gross margin 70.0%, +110 bpsOp. income $16.1mm, +12%Op. margin 25%Earnings per diluted share $0.60, +16%Cash up $16.9mm sequentially to $319.5mm Catheters (+27%) and grafts (+19%) drove Q2 sales growth. EMEA sales increased 23%, Americas 12%, and APAC 12%. Price accounted for 8% of sales growth and units 7%. Gross margin of 70.0% (vs. 68.9% in Q2 2024) increased due to higher average selling prices

BURLINGTON, Mass., July 08, 2025 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (NASDAQ:LMAT) announced today that it will release its second quarter 2025 financial results on Tuesday, August 5, 2025, after the market close. The company has scheduled a conference call for 5:00 PM EDT the same day to discuss the results, business highlights, and company outlook. Access to the live call is available by registering online here. All registrants will receive dial-in information and a PIN allowing them to access the live call. The audio webcast can also be accessed live or via replay through a webcast at ir.lemaitre.com. About LeMaitre LeMaitre is a provider of devices, implants, and services fo

BURLINGTON, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (NASDAQ:LMAT), a provider of vascular devices, implants, and services, today reported Q1 2025 results, announced a quarterly dividend of $0.20/share, and provided guidance. Q1 2025: Sales $59.9mm, +12% (+13% organic)Gross margin 69.2%, +60 bpsOp. income $12.6mm, +6%Op. margin 21%Earnings per diluted share $0.48, +10%Cash up $2.8mm sequentially to $302.5mm Grafts (+17%) and carotid shunts (+14%) drove sales growth. EMEA sales increased 18%, Americas 11%, and APAC 3%. Gross margin was 69.2% (vs. 68.6% in Q1 2024), due to higher average selling prices and manufacturing efficiencies. Operating income of $12.6mm wa

BURLINGTON, Mass., April 07, 2025 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (NASDAQ:LMAT) announced today that it will release its first quarter 2025 financial results on Thursday, May 1, 2025, after the market close. The company has scheduled a conference call for 5:00 PM EDT the same day to discuss the results, business highlights, and company outlook. Access to the live call is available by registering online here. All registrants will receive dial-in information and a PIN allowing them to access the live call. The audio webcast can also be accessed live or via replay through a webcast at www.lemaitre.com/investor. About LeMaitre LeMaitre is a provider of devices, implants, and ser

BURLINGTON, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- LeMaitre (NASDAQ:LMAT), a provider of vascular devices, implants, and services, reported Q4 2024 results, announced an increased quarterly dividend of $0.20/share (+25%), and provided guidance. Q4 2024 Financial Results Sales $55.7mm, +14% (+14% organic) vs. Q4 2023Gross margin 69.3%, +121 bpsOp. income $12.9mm, +26%Op. margin 23%Earnings per diluted share $0.49, +30%Cash up $175.8mm sequentially to $299.7mm Grafts (+23%), carotid shunts (+14%) and catheters (+12%) drove Q4 sales growth. APAC sales increased 21%, EMEA 18% and the Americas 12%. XenoSure patches received Chinese cardiac approval in December. The gross margin im

BURLINGTON, Mass., Jan. 27, 2025 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (NASDAQ:LMAT) announced today that it will release its fourth quarter 2024 financial results on Thursday, February 27, 2025, after the market close. The company has scheduled a conference call for 5:00 PM EST the same day to discuss the results, business highlights, and company outlook. Access to the live call is available by registering online here. All registrants will receive dial-in information and a PIN allowing them to access the live call. The audio webcast can also be accessed live or via replay through a webcast at www.lemaitre.com/investor. About LeMaitre LeMaitre is a provider of devices, implants, a

BURLINGTON, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- LeMaitre (NASDAQ:LMAT), a provider of vascular devices, implants, and services, reported Q3 2024 results, announced a $0.16/share quarterly dividend, and provided guidance. Q3 2024 Financial Results Sales $54.8mm, +16% (+16% organic) vs. Q3 2023Gross margin 67.8%, +280 bpsOp. income $13.1mm, +43%Op. margin 24%Earnings per diluted share $0.49, +46%Cash up $10.8mm sequentially to $123.9mm Grafts (+24%), patches (+13%) and carotid shunts (+18%) drove Q3 sales growth. APAC sales increased 24%, EMEA 22% and the Americas 12%. The gross margin increased to 67.8% (vs. 65.0% in Q3 2023), driven by price increases and manufacturing efficiencie

BURLINGTON, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (NASDAQ:LMAT) announced today that it will release its third quarter 2024 financial results on Thursday, October 31, 2024, after the market close. The company has scheduled a conference call for 5:00 PM ET the same day to discuss the results, business highlights, and company outlook. Access to the live call is available by registering online here. All registrants will receive dial-in information and a PIN allowing them to access the live call. The audio webcast can also be accessed live or via replay through a webcast at www.lemaitre.com/investor. About LeMaitre LeMaitre is a provider of devices, implants, and

BURLINGTON, Mass., Aug. 01, 2024 (GLOBE NEWSWIRE) -- LeMaitre (NASDAQ:LMAT), a provider of vascular devices, implants and services, today reported Q2 2024 results, announced a $0.16/share quarterly dividend and provided guidance. Q2 2024 Financial Results Sales $55.8mm, +11% (+12% organic) vs. Q2 2023  Gross margin 68.9%, +490 bpsOp. income $14.4mm, +52%Op. margin 26%Net income $11.8mm, +46%Earnings per diluted share $0.52, +44%Cash up $4.8mm sequentially to $113.1mm Allografts (+30%), bovine patches (+12%) and carotid shunts (+22%) led Q2 sales growth. APAC sales increased 20%, EMEA 13% and the Americas 10%. The gross margin increased to 68.9% (vs. 64.0% in Q2 2023), driven by manufac

BURLINGTON, Mass., July 16, 2024 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (NASDAQ:LMAT) announced today that it will release its second quarter 2024 financial results on Thursday, August 1, 2024, after the market close. The company has scheduled a conference call for 5:00 PM ET the same day to discuss the results, business highlights, and company outlook. Access to the live call is available by registering online here. All registrants will receive dial-in information and a PIN allowing them to access the live call. The audio webcast can also be accessed live or via replay through a webcast at www.lemaitre.com/investor. About LeMaitre LeMaitre is a provider of devices, implants, and s

BURLINGTON, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- LeMaitre (NASDAQ:LMAT), a provider of vascular devices, implants and services, today reported Q1 2024 results, announced a $0.16/share quarterly dividend and provided guidance. Q1 2024 Financial Results Sales $53.5mm, +14% (+11% organic) vs. Q1 2023  Gross margin 68.6%, +300 bpsOp. income $11.9mm, +51%Op. margin 22%Net income $9.9mm, +64%Earnings per diluted share $0.44, +62%Cash up $3.2mm sequentially to $108.3mm Allografts (+31%), bovine patches (+13%), carotid shunts (+27%) and distributed porcine patches drove Q1 sales. APAC sales increased 44%, EMEA 17% and the Americas 10%. The gross margin increased to 68.6% in Q1 (vs. 65.6% in

BURLINGTON, Mass., April 19, 2024 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (NASDAQ:LMAT) announced today that it will release its first quarter 2024 financial results on Thursday, May 2, 2024, after the market close. The company has scheduled a conference call for 5:00 PM ET the same day to discuss the results, business highlights, and company outlook. Access to the live call is available by registering online here. All registrants will receive dial-in information and a PIN allowing them to access the live call. The audio webcast can also be accessed live or via replay through a webcast at www.lemaitre.com/investor. About LeMaitre LeMaitre is a provider of devices, implants, and serv

BURLINGTON, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- LeMaitre (NASDAQ:LMAT), a provider of vascular devices, implants and services, today reported Q4 2023 results, announced a $0.16/share quarterly dividend and provided guidance. Q4 2023 Financial Results Sales $48.9mm, +19% (+14% organic) vs. Q4 2022Gross margin 68.1%, +450 bpsOp. income $10.2mm, +46%Op. margin 21%Net income $8.5mm, +50%Earnings per diluted share $0.38, +49%Cash up $8.1mm sequentially to $105.1mm Bovine patches (+18%), allografts (+52%), valvulotomes (+12%), carotid shunts (+16%) and distributed porcine patches drove Q4 sales. EMEA sales increased 21%, the Americas 20% and APAC 11%. The gross margin increased to 68.1%

BURLINGTON, Mass., Feb. 13, 2024 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (NASDAQ:LMAT) announced today that it will release its fourth quarter 2023 financial results on Tuesday, February 27, 2024, after the market close. The company has scheduled a conference call for 5:00 PM ET the same day to discuss the results, business highlights, and company outlook. Access to the live call is available by registering online here. All registrants will receive dial-in information and a PIN allowing them to access the live call. The audio webcast can also be accessed live or via replay through a webcast at www.lemaitre.com/investor. About LeMaitre LeMaitre is a provider of devices, implants, and

BURLINGTON, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- LeMaitre (NASDAQ:LMAT), a provider of vascular devices, implants and services, today reported Q3 2023 results, announced a $0.14/share quarterly dividend and provided guidance. Q3 2023 Financial Results Sales $47.4mm, +21% (+16% organic) vs. Q3 2022Gross margin 65.0%, +80 bpsOp. income $9.2mm, +49%Op. margin 19%Net income $7.5mm, +38%Earnings per diluted share $0.33, +36%Cash up $6.8mm to $97.0mm Bovine patches (+22%), valvulotomes (+27%), bovine grafts (+15%) and carotid shunts (+24%) drove Q3 sales. APAC sales increased 30%, EMEA 24% and the Americas 20%. The gross margin increased to 65.0% in Q3 (vs. 64.2% in Q3 2022) driven large

BURLINGTON, Mass., Oct. 17, 2023 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (NASDAQ:LMAT) announced today that it will release its third quarter 2023 financial results on Wednesday, November 1, 2023, after the market close. The company has scheduled a conference call for 5:00 PM EDT the same day to discuss the results, business highlights, and company outlook. Access to the live call is available by registering online here. All registrants will receive dial-in information and a PIN allowing them to access the live call. The audio webcast can also be accessed live or via replay through a webcast at www.lemaitre.com/investor. About LeMaitre LeMaitre is a provider of dev

BURLINGTON, Mass., Aug. 01, 2023 (GLOBE NEWSWIRE) -- LeMaitre (NASDAQ:LMAT), a provider of vascular devices, implants and services, today reported Q2 2023 results, announced a $0.14/share quarterly dividend and provided guidance. Q2 2023 Financial Results Sales $50.1mm, +19% (+16% organic) vs. Q2 2022Op. income $9.5mm, +63% (+8% adjusted)Op. margin 19%Net income $8.1mm, +130% (+27% adjusted)Earnings per diluted share $0.36, +127% (+25% adjusted)Cash up $9.2mm to $90.2mm Bovine patches (+16%), valvulotomes (+18%), bovine grafts (+13%), carotid shunts (+22%) and allografts (+18%) drove Q2 sales. EMEA was up 26%, APAC 21% and the Americas 16%. The gross margin decreased to 64.0% in Q2 (vs

BURLINGTON, Mass., July 17, 2023 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (NASDAQ:LMAT) announced today that it will release its second quarter 2023 financial results on Tuesday, August 1, 2023, after the market close. The company has scheduled a conference call for 5:00 PM ET the same day to discuss the results, business highlights, and company outlook. Access to the live call is available by registering online here. All registrants will receive dial-in information and a PIN allowing them to access the live call. The audio webcast can also be accessed live or via replay through a webcast at www.lemaitre.com/investor. About LeMaitre LeMaitre is a provider of devices, implants, and se

BURLINGTON, Mass., May 02, 2023 (GLOBE NEWSWIRE) -- LeMaitre (NASDAQ:LMAT), a provider of vascular devices, implants and services, today reported Q1 2023 results, announced a $0.14/share quarterly dividend and provided guidance. Q1 2023 Financial Results  Sales $47.1mm, +19% (+22% organic) vs. Q1 2022Op. income $7.9mm, -1%Op. margin 17%Net income $6.0mm, flatEarnings per diluted share $0.27, -1% Valvulotomes (+29%), carotid patches (+17%), bovine grafts (+22%), allografts (+42%) and carotid shunts (+18%) drove record sales in Q1. Sales increased 21% in the Americas, 17% in EMEA, and 6% in APAC. The gross margin was 65.6%, flat vs. Q1 2022, helped by price increases and manufacturing ef

BURLINGTON, Mass., April 17, 2023 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (NASDAQ:LMAT) announced today that it will release its first quarter 2023 financial results on Tuesday, May 2, 2023, after the market close. The company has scheduled a conference call for 5:00 PM ET the same day to discuss the results, business highlights, and company outlook. Access to the live call is available by registering online here. All registrants will receive dial-in information and a PIN allowing them to access the live call. The audio webcast can also be accessed live or via replay through a webcast at www.lemaitre.com/investor. About LeMaitre LeMaitre is a provider of devices, implants and servic

BURLINGTON, Mass., Feb. 23, 2023 (GLOBE NEWSWIRE) -- LeMaitre (NASDAQ:LMAT), a provider of vascular devices, implants and services, today reported Q4 2022 results, announced a $0.14/share quarterly dividend (+12%) and provided guidance. Q4 2022 Financial Results Sales $41.0mm, +4% (+8% organic) vs. Q4 2021Op. income $7.0mm, -16%Op. margin 17%Net income $5.6mm, -9%Earnings per diluted share $0.25, -9%Cash and investments +$3.0mm to $82.7mm Bovine patches (+11%), carotid shunts (+24%) and bovine grafts (+11%) drove sales growth in Q4 2022. Organic sales increased 22% in APAC, 9% in EMEA and 6% in the Americas. APAC and EMEA each reported record sales. The gross margin decreased to 63.6%

BURLINGTON, Mass., Feb. 08, 2023 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (NASDAQ:LMAT) announced today that it will release its fourth quarter 2022 financial results on Thursday, February 23, 2023, after the market close. The company has scheduled a conference call for 5:00 PM ET the same day to discuss the results, business highlights, and company outlook. Access to the live call is available by registering online here. All registrants will receive dial-in information and a PIN allowing them to access the live call. The audio webcast can also be accessed live or via replay through a webcast at www.lemaitre.com/investor. About LeMaitre LeMaitre is a provider of devices, implants and

BURLINGTON, Mass., Oct. 27, 2022 (GLOBE NEWSWIRE) -- LeMaitre (NASDAQ:LMAT), a provider of vascular devices, implants and services, today reported Q3 2022 results, announced a $0.125/share quarterly dividend and provided guidance. Q3 2022 Financial Results Sales of $39.0mm, +2% (+7% organic) vs. Q3 2021Op. income $6.2mm, -32%Op. margin of 16%Net income of $5.5mm, -16%Earnings per diluted share $0.25, -17%Cash and investments +$4.1mm to $79.7mm Q3 2022 sales growth was driven by carotid shunts (+23%), Artegraft (+12%), allografts (+10%) and embolectomy catheters (+10%). By geography, organic sales increased 11% in APAC, 8% in EMEA and 6% in the Americas. The strong U.S. dollar reduced sa

BURLINGTON, Mass., Oct. 17, 2022 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (NASDAQ:LMAT) announced today that it will release its third quarter 2022 financial results on Thursday, October 27, 2022, after the market close. The company has scheduled a conference call for 5:00 PM ET the same day to discuss the results, business highlights, and company outlook. Access to the live call is available by registering online here. All registrants will receive dial-in information and a PIN allowing them to access the live call. The audio webcast can also be accessed live or via replay through a webcast at www.lemaitre.com/investor. About LeMaitre LeMaitre is a provider of devices, implants and s

BURLINGTON, Mass., July 28, 2022 (GLOBE NEWSWIRE) -- LeMaitre (NASDAQ:LMAT), a provider of vascular devices, implants and services, today reported Q2 2022 results, announced a $0.125/share quarterly dividend and provided guidance. Q2 2022 Financial Results Sales of $42.1mm, +4% (+8% organic) vs. Q2 2021Gross margin of 66.0%Op. income reported $5.8mm, -48%Op. income ex. special charge $8.9mm, -20%Earnings per diluted share reported $0.16, -60%Earnings per diluted share ex. special charge $0.29, -26%Cash and investments +$4.8mm to $75.7mm Biologics drove Q2 2022 sales growth: XenoSure (+21%), allografts (+25%) and Artegraft (+11%). Q2 organic sales growth was led by EMEA (+11%) and APAC (

BURLINGTON, Mass., July 18, 2022 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (NASDAQ:LMAT) announced today that it will release its second quarter 2022 financial results on Thursday, July 28, 2022, after the market close. The company has scheduled a conference call for 5:00 PM ET the same day to discuss the results, business highlights, and company outlook. Access to the live call is available by registering online here. All registrants will receive dial-in information and a PIN allowing them to access the live call. The audio webcast can also be accessed live or via replay through a webcast at www.lemaitre.com/investor. About LeMaitre LeMaitre is a provider of devices, implants and ser

BURLINGTON, Mass., April 28, 2022 (GLOBE NEWSWIRE) -- LeMaitre (NASDAQ:LMAT), a provider of vascular devices, implants and services, today reported Q1 2022 results, announced a $0.125/share quarterly dividend and provided guidance. Q1 2022 Financial Results Sales of $39.6mm, +10% (+13% organic) vs. Q1 2021Op. income of $7.9mm, +0%Op. margin of 20%Net income of $6.0mm, +2%Earnings of $0.27 per diluted share, -4%Cash and investments +$0.9mm to $70.9mm Q1 2022 sales growth was driven by Artegraft, XenoSure, carotid shunts, allografts and valvulotomes. By geography, sales were driven by the Americas (+12%), EMEA (+6%) and APAC (+9%). The gross margin decreased to 65.6% (vs. 66.3% in Q1 202

BURLINGTON, Mass., April 15, 2022 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (NASDAQ:LMAT) announced today that it will release its first quarter 2022 financial results on Thursday, April 28, 2022, after the market close. The company has scheduled a conference call for 5:00 PM ET the same day to discuss the results, business highlights, and company outlook. Access to the live call is available by dialing 844-239-5284 (+1-512-961-6497 for international callers), passcode 8054167. The call can also be accessed live or via replay through a webcast at www.lemaitre.com/investor. About LeMaitre LeMaitre is a provider of devices, implants and services for the treatment of peripheral vascular

BURLINGTON, Mass., Feb. 24, 2022 (GLOBE NEWSWIRE) -- LeMaitre (NASDAQ:LMAT), a provider of vascular devices, implants and services, today reported Q4 2021 results, announced a $0.125/share quarterly dividend (+14%) and provided guidance. Q4 2021 Financial Results Sales of $39.5mm, +5% (+6% organic) vs. Q4 2020Op. income of $8.3mm, -13%Op. margin of 21%Net income of $6.2mm, -12%Earnings of $0.28 per diluted share, -18%Cash and investments +$2.9mm to $70.0mm Q4 2021 sales were driven by bovine grafts (Artegraft) and bovine patches (XenoSure). The Americas was up 8%, EMEA was up 1%, and Asia/Pac was down 3%. The gross margin increase to 65.7% (vs. 65.0% in Q4 2020) was driven by higher av

BURLINGTON, Mass., Feb. 11, 2022 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (NASDAQ:LMAT) announced today that it will release its fourth quarter 2021 financial results on Thursday, February 24, 2022, after the market close. The company has scheduled a conference call for 5:00 PM ET the same day to discuss the results, business highlights, and company outlook. Access to the live call is available by dialing 800-773-2954 (+1-847-413-3731 for international callers), passcode 50283055. The call can also be accessed live or via replay through a webcast at www.lemaitre.com/investor. About LeMaitre LeMaitre is a provider of devices, implants and services for the treatment of peripheral vascu

BURLINGTON, Mass., Oct. 28, 2021 (GLOBE NEWSWIRE) -- LeMaitre (NASDAQ:LMAT), a provider of vascular devices, implants and services, today reported Q3 2021 results, announced an $0.11/share quarterly dividend and provided guidance. Q3 2021 Financial Results Sales of $38.4mm, +5% (+5% organic) vs. Q3 2020Gross margin of 64.8%, +250 basis pointsOp. income of $9.1mm, -9%Op. margin of 24%Net income of $6.5mm, -13%Earnings of $0.30 per diluted share, -19%EBITDA of $11.3mm, -10% Q3 2021 sales were driven by Artegraft, allografts and valvulotomes. The Americas and EMEA both grew 5%, while APAC was up 16%. Due to the Delta variant, many hospitals deferred elective surgeries. The 250 basis point

BURLINGTON, Mass., Oct. 14, 2021 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (NASDAQ:LMAT) announced today that it will release its third quarter 2021 financial results on Thursday, October 28, 2021, after the market close. The company has scheduled a conference call for 5:00 PM ET the same day to discuss the results, business highlights, and company outlook. Access to the live call is available by dialing 844-239-5284 (+1-512-961-6497 for international callers), passcode 8308248. The call can also be accessed live or via replay through a webcast at www.lemaitre.com/investor. About LeMaitre LeMaitre is a provider of devices, implants and services for the treatment of peripheral vascular

BURLINGTON, Mass., July 29, 2021 (GLOBE NEWSWIRE) -- LeMaitre (NASDAQ:LMAT), a provider of vascular devices, implants and services, today reported Q2 2021 results, announced an $0.11/share quarterly dividend and provided guidance. Q2 2021 Financial Results Sales of $40.7mm, +64% (+35% organic) vs. Q2 2020Op. income of $11.1mm, +128%Op. margin of 27%Net income of $8.3mm, +137%Earnings of $0.40 per diluted share, +131%EBITDA of $13.3mm, +108% Q2 2021 sales were driven by Artegraft ($6.7mm), valvulotomes, carotid shunts, patches and allografts. By geography, the Americas was up 83%, Europe/Middle East/Africa +36% and Asia/Pac +30%. The gross margin decline to 65.8% (vs. 68.5% in Q2 20